IVIEW Therapeutics develops targeted small molecule therapies and gene therapies for viral conjunctivitis, utilizing TRPM8 agonist technology and liposomal drug delivery systems. The company addresses the unmet medical need for effective treatments in ocular health, particularly for conditions like dry eye and myopia.
Funding
$30.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Viral conjunctivitis lacks targeted and effective treatments, creating an unmet need in ocular health. Current therapies may not address the underlying viral cause or provide sufficient relief from symptoms. This can lead to prolonged discomfort and potential complications for patients.
Solution
iVIEW Therapeutics is developing targeted small molecule therapies and gene therapies for viral conjunctivitis. The company utilizes TRPM8 agonist technology to modulate nerve activity and liposomal drug delivery systems to enhance drug penetration and efficacy in the eye. This approach aims to provide more effective and targeted treatments for ocular conditions, addressing the limitations of existing therapies. iVIEW's pipeline focuses on innovative science to create differentiated products that fulfill unmet medical needs in ophthalmology.
Target Audience
The primary target audience includes patients suffering from viral conjunctivitis and other ocular conditions, as well as ophthalmologists and other eye care professionals seeking more effective treatment options.
Features
- TRPM8 agonist technology for targeted nerve modulation
- Liposomal drug delivery systems for enhanced drug penetration
- Target-based small molecule discovery
- Gene therapy development
- I-Gel in-situ gel technology
- IVW-1001 ophthalmic eyelid wipe for dry eye disease